Zydus cleared to begin US trial of oral therapy usnoflast for ALS
1 day ago · Zydus said results from that study will be presented at an “upcoming medical conference” and published in a medical journal. That proof-of-concept Phase 2a trial …
Zydus announces USFDA Orphan Drug Designation for Usnoflast …
3 days ago · Zydus has also received approval from the USFDA to initiate a Phase 2(b) clinical trial for Usnoflast in ALS patients. This trial will be a randomized, double-blind, placebo …
FDA approves Zydus' trial of Usnoflast for ALS treatment
6 days ago · Zydus is committed to unlocking new frontiers in neuroscience and developing transformative breakthrough medicines.” Also known as ZYIL1, Usnoflast has been explored in …
Zydus Usnoflast gets USFDA Orphan Drug Designation for …
3 days ago · Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that the U.S. Food and Drug Administration (USFDA) has granted Orphan Drug …
Zydus receives USFDA Orphan Drug Designation for Usnoflast to …
3 days ago · Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for treating amyotrophic lateral sclerosis (ALS), a rare …
Zydus Phase II (b) Clinical Trial: Zydus gets USFDA nod to conduct ...
6 days ago · Ahmedabad: Indian drug maker Zydus has received approval from USFDA to conduct Phase II(b) clinical trial to determine the optimal dosage strength of Usnoflast, a novel …
Zydus Lifesciences Receives Approval from USFDA to Conduct …
Jan 18, 2025 · The USFDA has granted Zydus an 'Orphan Drug Designation' for Usnoflast to treat patients with Cryopyrin Associated Periodic Syndrome (CAPS), a rare auto-inflammatory …
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus. Studies have demonstrated that ZYIL1 is highly potent in human whole blood assay and can suppress …
Zydus, a leading discovery-based, global pharmaceutical company, announced the completion of its Phase II(a) clinical study of NLRP3 inhibitor ‘Usnoflast (ZYIL1)’ in patients with Amyotrophic …
Zydus, a leading discovery-based, global pharmaceutical company, announced today that it has completed enrolment of its Phase II clinical study of NLRP3 inhibitor ‘Usnoflast (ZYIL1)’ in …
- Some results have been removed